Efficacy of Imatinib Mesylate in Hypereosinophilic Syndromes (NILG-HES1-03)
Therapeutic and Biological Effects of Imatinib Mesylate in Primary Hypereosinophilic Syndromes
Sponsor: Northern Italy Leukemia Group
A PHASE2 clinical study on Chronic Eosinophilic Leukemia and Chronic Idiopathic Hypereosinophilia, this trial is completed. The trial is conducted by Northern Italy Leukemia Group and has accumulated 6 data snapshots since 2004. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Northern Italy Leukemia Group
For direct contact, visit the study record on ClinicalTrials.gov .